Back to Peptide Database
RecoveryResearch Phase

FGL Peptide

Overview

FGL peptide is a 15-amino acid synthetic sequence derived from the neural cell adhesion molecule (NCAM) that mimics the fibronectin-like domain. It promotes neurite outgrowth and synaptic plasticity by engaging NCAM and fibroblast growth factor receptors without requiring direct cell-cell adhesion. The peptide has been investigated for neuroprotective and cognitive-enhancing properties in models of neurological injury and disease.

Key Research Findings

Preclinical rodent studies have demonstrated improved spatial learning and memory in models of aging and neurodegeneration. Research published in the Journal of Neuroscience and related journals has shown FGL enhances hippocampal long-term potentiation and protects against excitotoxic injury. Human clinical trials have not been reported in peer-reviewed literature.

Route of Administration

Subcutaneous injection, Intranasal

Regulatory Status

Research Phase

Interested in FGL Peptide?

Find a verified provider experienced with FGL Peptide protocols in your area. All providers are credentialed and use compliant sourcing.

Find a FGL Peptide Provider

Related Peptides

BPC-157

Research Phase

A synthetic gastric pentadecapeptide derived from a protein found in human gastric juice. BPC-157 promotes angiogenesis and the expression of growth factors including VEGF, EGF, and NO-mediated pathways. It has demonstrated cytoprotective and wound-healing properties across multiple tissue types in preclinical models, including tendon, muscle, ligament, and gastrointestinal mucosa.

TB-500 (Thymosin Beta-4)

In Clinical Trials

Thymosin Beta-4 is a 43-amino acid actin-sequestering protein involved in cell migration, differentiation, and tissue repair. It promotes wound healing by upregulating cell-building proteins such as actin and laminin, facilitating cell migration to sites of injury. TB-500 also has anti-inflammatory properties mediated through NF-kB pathway modulation.

GHK-Cu

Research Phase

A naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. GHK-Cu activates tissue remodeling by stimulating collagen synthesis, glycosaminoglycan production, and angiogenesis while suppressing fibrinogen synthesis. It modulates the activity of matrix metalloproteinases and influences over 4,000 genes related to tissue repair.

DSIP (Delta Sleep-Inducing Peptide)

Research Phase

A naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from cerebral venous blood of rabbits during induced sleep. DSIP modulates sleep architecture by promoting delta wave (slow-wave) sleep through interactions with the GABAergic system and hypothalamic sleep centers. It also exhibits stress-protective, analgesic, and neuromodulatory properties.